EP3411058 - COMBINATION THERAPY WITH A6 AND PACLITAXEL FOR THE TREATMENT OF OVARIAN CANCER [Right-click to bookmark this link] | |||
Former [2018/50] | COMBINATION THERAPY WITH A6, CHEMOTHERAPEUTIC AGENTS, RADIATION THERAPY, OR A COMBINATION THEREOF FOR THE TREATMENT OF CANCER | ||
[2022/22] | Status | No opposition filed within time limit Status updated on 12.01.2024 Database last updated on 31.08.2024 | |
Former | The patent has been granted Status updated on 03.02.2023 | ||
Former | Grant of patent is intended Status updated on 26.07.2022 | ||
Former | Examination is in progress Status updated on 19.02.2021 | ||
Former | Request for examination was made Status updated on 09.11.2018 | ||
Former | The international publication has been made Status updated on 11.08.2017 | Most recent event Tooltip | 24.05.2024 | Lapse of the patent in a contracting state New state(s): IT | published on 26.06.2024 [2024/26] | Applicant(s) | For all designated states Splash Pharmaceuticals, Inc. 4365 Executive Drive Suite 1500 San Diego, CA 92121 / US | [2023/10] |
Former [2018/50] | For all designated states Splash Pharmaceuticals, Inc. 4365 Executive Drive Suite 1500 San Diego, CA 92121 / US | Inventor(s) | 01 /
FINLAYSON, Malcolm c/o Splash Pharmaceuticals 4365 Executive Drive Suite 1500 San Diego, CA 92121 / US | 02 /
NELSON, David c/o Splash Pharmaceuticals 4365 Executive Drive Suite 1500 San Diego, CA 92121 / US | [2018/50] | Representative(s) | Meissner Bolte Partnerschaft mbB Patentanwälte Rechtsanwälte Postfach 86 06 24 81633 München / DE | [N/P] |
Former [2023/10] | Held, Stephan, et al Meissner Bolte Patentanwälte Rechtsanwälte Partnerschaft mbB Widenmayerstraße 47 80538 München / DE | ||
Former [2018/50] | Jones Day Rechtsanwälte, Attorneys-at-Law, Patentanwälte Prinzregentenstrasse 11 80538 München / DE | Application number, filing date | 17747995.3 | 31.01.2017 | [2018/50] | WO2017US15754 | Priority number, date | US201662290306P | 02.02.2016 Original published format: US 201662290306 P | US201662314867P | 29.03.2016 Original published format: US 201662314867 P | US201662368964P | 29.07.2016 Original published format: US 201662368964 P | [2018/50] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2017136312 | Date: | 10.08.2017 | Language: | EN | [2017/32] | Type: | A1 Application with search report | No.: | EP3411058 | Date: | 12.12.2018 | Language: | EN | The application published by WIPO in one of the EPO official languages on 10.08.2017 takes the place of the publication of the European patent application. | [2018/50] | Type: | B1 Patent specification | No.: | EP3411058 | Date: | 08.03.2023 | Language: | EN | [2023/10] | Search report(s) | International search report - published on: | US | 10.08.2017 | (Supplementary) European search report - dispatched on: | EP | 02.08.2019 | Classification | IPC: | A61K45/06, A61K31/337, A61K33/243, A61K38/08, C07K7/06, A61P35/00, A61P35/04 | [2022/22] | CPC: |
C07K7/06 (EP);
A61K45/06 (EP,US);
A61K31/337 (EP,US);
A61K33/243 (EP,US);
A61K38/08 (EP,US);
A61P35/00 (EP);
| C-Set: |
A61K31/337, A61K2300/00 (EP);
A61K33/243, A61K2300/00 (EP);
A61K38/08, A61K2300/00 (EP)
|
Former IPC [2018/50] | A61K38/04, A61K38/08, C07K7/06, A61P35/00, A61P35/04 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2018/50] | Extension states | BA | Not yet paid | ME | Not yet paid | Validation states | MA | Not yet paid | MD | Not yet paid | Title | German: | KOMBINATIONSTHERAPIE MIT A6 UND PACLITAXEL ZUR BEHANDLUNG DES OVARIALKARZINOMS | [2022/22] | English: | COMBINATION THERAPY WITH A6 AND PACLITAXEL FOR THE TREATMENT OF OVARIAN CANCER | [2022/22] | French: | POLYTHÉRAPIE AVEC A6 ET PACLITAXEL POUR LE TRAITEMENT DU CANCER DES OVAIRES | [2022/22] |
Former [2018/50] | KOMBINATIONSTHERAPIE MIT A6, CHEMOTHERAPEUTIKA, STRAHLENTHERAPIE ODER KOMBINATION DAVON ZUR BEHANDLUNG VON KREBS | ||
Former [2018/50] | COMBINATION THERAPY WITH A6, CHEMOTHERAPEUTIC AGENTS, RADIATION THERAPY, OR A COMBINATION THEREOF FOR THE TREATMENT OF CANCER | ||
Former [2018/50] | POLYTHÉRAPIE AVEC A6, AGENTS DE CHIMIOTHÉRAPIE, RADIOTHÉRAPIE OU UNE COMBINAISON DE CES DENIERS POUR LE TRAITEMENT DU CANCER | Entry into regional phase | 27.07.2018 | National basic fee paid | 27.07.2018 | Search fee paid | 27.07.2018 | Designation fee(s) paid | 27.07.2018 | Examination fee paid | Examination procedure | deleted | Date on which the examining division has become responsible | 27.07.2018 | Examination requested [2018/50] | 02.03.2020 | Amendment by applicant (claims and/or description) | 18.02.2021 | Despatch of a communication from the examining division (Time limit: M06) | 30.08.2021 | Reply to a communication from the examining division | 27.07.2022 | Communication of intention to grant the patent | 03.01.2023 | Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time | 16.01.2023 | Fee for grant paid | 16.01.2023 | Fee for publishing/printing paid | 16.01.2023 | Receipt of the translation of the claim(s) | Opposition(s) | 11.12.2023 | No opposition filed within time limit [2024/07] | Request for further processing for: | The application is deemed to be withdrawn due to failure to fulfill actions required for granting the patent | 16.01.2023 | Request for further processing filed | 16.01.2023 | Full payment received (date of receipt of payment) Request granted | 24.01.2023 | Decision despatched | Fees paid | Renewal fee | 15.01.2019 | Renewal fee patent year 03 | 30.01.2020 | Renewal fee patent year 04 | 27.01.2021 | Renewal fee patent year 05 | 27.01.2022 | Renewal fee patent year 06 | 27.01.2023 | Renewal fee patent year 07 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | AT | 08.03.2023 | CZ | 08.03.2023 | DK | 08.03.2023 | EE | 08.03.2023 | ES | 08.03.2023 | FI | 08.03.2023 | HR | 08.03.2023 | IT | 08.03.2023 | LT | 08.03.2023 | LV | 08.03.2023 | NL | 08.03.2023 | PL | 08.03.2023 | RO | 08.03.2023 | RS | 08.03.2023 | SE | 08.03.2023 | SI | 08.03.2023 | SK | 08.03.2023 | SM | 08.03.2023 | NO | 08.06.2023 | GR | 09.06.2023 | IS | 08.07.2023 | PT | 10.07.2023 | [2024/26] |
Former [2024/10] | AT | 08.03.2023 | |
CZ | 08.03.2023 | ||
DK | 08.03.2023 | ||
EE | 08.03.2023 | ||
ES | 08.03.2023 | ||
FI | 08.03.2023 | ||
HR | 08.03.2023 | ||
LT | 08.03.2023 | ||
LV | 08.03.2023 | ||
NL | 08.03.2023 | ||
PL | 08.03.2023 | ||
RO | 08.03.2023 | ||
RS | 08.03.2023 | ||
SE | 08.03.2023 | ||
SI | 08.03.2023 | ||
SK | 08.03.2023 | ||
SM | 08.03.2023 | ||
NO | 08.06.2023 | ||
GR | 09.06.2023 | ||
IS | 08.07.2023 | ||
PT | 10.07.2023 | ||
Former [2023/50] | AT | 08.03.2023 | |
CZ | 08.03.2023 | ||
EE | 08.03.2023 | ||
ES | 08.03.2023 | ||
FI | 08.03.2023 | ||
HR | 08.03.2023 | ||
LT | 08.03.2023 | ||
LV | 08.03.2023 | ||
NL | 08.03.2023 | ||
PL | 08.03.2023 | ||
RO | 08.03.2023 | ||
RS | 08.03.2023 | ||
SE | 08.03.2023 | ||
SK | 08.03.2023 | ||
SM | 08.03.2023 | ||
NO | 08.06.2023 | ||
GR | 09.06.2023 | ||
IS | 08.07.2023 | ||
PT | 10.07.2023 | ||
Former [2023/49] | AT | 08.03.2023 | |
CZ | 08.03.2023 | ||
EE | 08.03.2023 | ||
ES | 08.03.2023 | ||
FI | 08.03.2023 | ||
HR | 08.03.2023 | ||
LT | 08.03.2023 | ||
LV | 08.03.2023 | ||
NL | 08.03.2023 | ||
RO | 08.03.2023 | ||
RS | 08.03.2023 | ||
SE | 08.03.2023 | ||
SM | 08.03.2023 | ||
NO | 08.06.2023 | ||
GR | 09.06.2023 | ||
PT | 10.07.2023 | ||
Former [2023/48] | AT | 08.03.2023 | |
EE | 08.03.2023 | ||
ES | 08.03.2023 | ||
FI | 08.03.2023 | ||
HR | 08.03.2023 | ||
LT | 08.03.2023 | ||
LV | 08.03.2023 | ||
NL | 08.03.2023 | ||
RS | 08.03.2023 | ||
SE | 08.03.2023 | ||
SM | 08.03.2023 | ||
NO | 08.06.2023 | ||
GR | 09.06.2023 | ||
PT | 10.07.2023 | ||
Former [2023/46] | ES | 08.03.2023 | |
FI | 08.03.2023 | ||
HR | 08.03.2023 | ||
LT | 08.03.2023 | ||
LV | 08.03.2023 | ||
NL | 08.03.2023 | ||
RS | 08.03.2023 | ||
SE | 08.03.2023 | ||
SM | 08.03.2023 | ||
NO | 08.06.2023 | ||
GR | 09.06.2023 | ||
PT | 10.07.2023 | ||
Former [2023/38] | ES | 08.03.2023 | |
FI | 08.03.2023 | ||
HR | 08.03.2023 | ||
LT | 08.03.2023 | ||
LV | 08.03.2023 | ||
NL | 08.03.2023 | ||
RS | 08.03.2023 | ||
SE | 08.03.2023 | ||
NO | 08.06.2023 | ||
GR | 09.06.2023 | ||
Former [2023/37] | ES | 08.03.2023 | |
FI | 08.03.2023 | ||
HR | 08.03.2023 | ||
LT | 08.03.2023 | ||
LV | 08.03.2023 | ||
RS | 08.03.2023 | ||
SE | 08.03.2023 | ||
NO | 08.06.2023 | ||
GR | 09.06.2023 | ||
Former [2023/36] | ES | 08.03.2023 | |
FI | 08.03.2023 | ||
HR | 08.03.2023 | ||
LT | 08.03.2023 | ||
LV | 08.03.2023 | ||
RS | 08.03.2023 | ||
SE | 08.03.2023 | ||
NO | 08.06.2023 | ||
Former [2023/35] | ES | 08.03.2023 | |
HR | 08.03.2023 | ||
LT | 08.03.2023 | ||
RS | 08.03.2023 | ||
NO | 08.06.2023 | ||
Former [2023/34] | ES | 08.03.2023 | |
LT | 08.03.2023 | ||
RS | 08.03.2023 | ||
Former [2023/33] | ES | 08.03.2023 | |
LT | 08.03.2023 | Documents cited: | Search | [XY]WO2010102253 (ANGSTROM PHARMACEUTICALS INC [US], et al) [X] 1,4,6,7,9-11 * whole ddocument esp. pages 1-2,4,7,12,21,25;claims 46,57-61 * [Y] 1-15; | [Y]WO2011022335 (SINAI SCHOOL MEDICINE [US], et al) [Y] 1-15* whole document esp.paragraphs [16,92,94,95,97,98,127,129,252-253,260] *; | [XY]WO2011109678 (ANGSTROM PHARMACEUTICALS INC [US], et al) [X] 1,4,6,7,9-11 * whole document esp. paragraphs [2,30,35,38,41,43,44,54,59,90,105,197,207,266]; claim 1 * [Y] 1-15 | International search | [Y]US2006088511 (TAI ISABELLA T [CA], et al) [Y] 27, 30* para [0211], [0214] *; | [XY]US2011053864 (FINLAYSON MALCOLM [US], et al) [X] 1-6, 24-26, 28, 29, 33-38, 55-58 * para [0035], [0043], [0052], [0056], [0104], [0107], [0109], [0142], [0189] SEQ ID NO: 1 * [Y] 27, 30 | by applicant | US5994309 | US6696416 | US6963587 | US2009192085 | - "Peptidomimetics for Drug Design", GOODMANRO, Burger's Medicinal Chemistry and Drug Discovery, John Wiley & Sons, (19950000), vol. 1, pages 803 - 861 |